Efficacy and Safety of Temozolomide-based Regimens in Advanced Pancreatic Neuroendocrine Tumors: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 12

PMID 38347461

Authors

Erfan Taherifard

Muhammad Bakhtiar

Mahnoor Mahnoor

Rabeea Ahmed

Ludimila Cavalcante

Janie Zhang

Anwaar Saeed

Affiliations

Soon will be listed here.

Abstract

Background: Recent advances in the management of pancreatic neuroendocrine tumors (pNETs) highlight the potential benefits of temozolomide, an alkylating agent, for these patients. In this meta-analysis, we aimed to assess the outcome of temozolomide, alone or in combination with other anticancer medications in patients with advanced pNET.

Methods: Online databases of PubMed, Web of Science, Embase, the Cochrane Library, and ClinicalTrials.gov were searched systematically for clinical trials that reported the efficacy and safety of temozolomide in patients with advanced pNET. Random-effect model was utilized to estimate pooled rates of outcomes based on Response Evaluation Criteria in Solid Tumors criteria, biochemical response, and adverse events (AEs).

Results: A total of 14 studies, providing details of 441 individuals with advanced pNET, were included. The quantitative analyses showed a pooled objective response rate (ORR) of 41.2% (95% confidence interval, CI, of 32.4%-50.6%), disease control rate (DCR) of 85.3% (95% CI of 74.9%-91.9%), and a more than 50% decrease from baseline chromogranin A levels of 44.9% (95% CI of 31.6%-49.0%). Regarding safety, the results showed that the pooled rates of nonserious AEs and serious AEs were 93.8% (95% CI of 88.3%-96.8%) and 23.7% (95% CI of 12.0%-41.5%), respectively. The main severe AEs encompassed hematological toxicities.

Conclusions: In conclusion, our meta-analysis suggests that treatment with temozolomide, either as a monotherapy or in combination with other anticancer treatments might be an effective and relatively safe option for patients with advanced locally unresectable and metastatic pNET. However, additional clinical trials are required to further strengthen these findings. This study has been registered in PROSPERO (CRD42023409280).

Citing Articles

Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin.

Mukherjee S, Pattnaik H, Sonti S, Ramesh M, Jain P, Ramirez R Cancers (Basel). 2025; 17(2).

PMID: 39858006 PMC: 11763628. DOI: 10.3390/cancers17020224.

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Baudin E, Capdevila J, Horsch D, Singh S, Caplin M, Wolin E Endocr Relat Cancer. 2024; 31(9).

PMID: 38913539 PMC: 11301421. DOI: 10.1530/ERC-23-0337.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Zhang J, Stevens M, Bradshaw T . Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2011; 5(1):102-14. DOI: 10.2174/1874467211205010102. View

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

Donadio M, Brito A, Riechelmann R . A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors. Ther Adv Med Oncol. 2023; 15:17588359231156218. PMC: 10026121. DOI: 10.1177/17588359231156218. View

Zaidi M, Lopez-Aguiar A, Switchenko J, Lipscomb J, Andreasi V, Partelli S . A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg. 2019; 270(3):422-433. PMC: 6697205. DOI: 10.1097/SLA.0000000000003461. View

Kulke M, Stuart K, Enzinger P, Ryan D, Clark J, Muzikansky A . Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006; 24(3):401-6. DOI: 10.1200/JCO.2005.03.6046. View

Shah R, Merlin M, Adant S, Zine-Eddine F, Beauregard J, Shah G . Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers (Basel). 2021; 13(2). PMC: 7828052. DOI: 10.3390/cancers13020232. View

Halfdanarson T, Rubin J, Farnell M, Grant C, Petersen G . Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008; 15(2):409-27. PMC: 2693313. DOI: 10.1677/ERC-07-0221. View

Bison S, Haeck J, Bol K, Koelewijn S, Groen H, Melis M . Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res. 2015; 5(1):62. PMC: 4639542. DOI: 10.1186/s13550-015-0142-y. View

10.

Stevens M, Hickman J, Langdon S, Chubb D, Vickers L, Stone R . Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987; 47(22):5846-52. View

11.

Almond L, Hodson J, Ford S, Gourevitch D, Roberts K, Shah T . Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. Eur J Surg Oncol. 2017; 43(10):1808-1815. DOI: 10.1016/j.ejso.2017.05.016. View

12.

Raj N, Reidy-Lagunes D . Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2015; 30(1):119-33. PMC: 5046222. DOI: 10.1016/j.hoc.2015.09.005. View

13.

Kunz P, Graham N, Catalano P, Nimeiri H, Fisher G, Longacre T . Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2022; 41(7):1359-1369. PMC: 9995105. DOI: 10.1200/JCO.22.01013. View

14.

Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks R . High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm. 2009; 24(5):527-33. DOI: 10.1089/cbr.2009.0644. View

15.

Brock C, Newlands E, Wedge S, Bower M, Evans H, Colquhoun I . Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58(19):4363-7. View

16.

Wesolowski J, Rajdev P, Mukherji S . Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010; 31(8):1383-4. PMC: 7966084. DOI: 10.3174/ajnr.A2170. View

17.

Chan J, Blaszkowsky L, Stuart K, Zhu A, Allen J, Wadlow R . A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013; 119(17):3212-8. PMC: 4308727. DOI: 10.1002/cncr.28142. View

18.

Campana D, Walter T, Pusceddu S, Gelsomino F, Graillot E, Prinzi N . Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine. 2017; 60(3):490-498. DOI: 10.1007/s12020-017-1474-3. View

19.

Claringbold P, Brayshaw P, Price R, Turner J . Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010; 38(2):302-11. DOI: 10.1007/s00259-010-1631-x. View

20.

Ryan C, Saif A, Rocha F, Philip P, Hernandez J, Ahmad S . Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2022; 30(3):1302-1304. DOI: 10.1245/s10434-022-12906-1. View